We are live on ! Find out more
AWGLSCP

ABG-WTT Global Life Science Capital Partners Portfolio holdings

AUM $12.3M
1-Year Est. Return 3.13%
This Fund
S&P 500
This Quarter Est. Return
-11.78%
1 Year Est. Return
-3.13%
3 Year Est. Return
+108.96%
5 Year Est. Return
-90.91%
10 Year Est. Return
AUM
$51.7M
AUM Growth
-$39.9M
Cap. Flow
-$31.4M
Cap. Flow %
-60.69%
Top 10 Hldgs %
100%
Holding
2
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LUNG icon
Pulmonx
LUNG
+$31.4M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
MDVL
1
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$47.6M 92%
77,719
LUNG icon
2
Pulmonx
LUNG
$87.6M
$4.14M 8%
93,831
-721,188
-88% -$31.4M

Similar funds

ABG-WTT Global Life Science Capital Partners's Q2 2021 Portfolio in Review

As of Q2 2021, ABG-WTT Global Life Science Capital Partners held 2 positions worth $51.7M, down 44% from $91.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

ABG-WTT Global Life Science Capital Partners withdrew a net $31.4M in Q2 2021, reducing 1 holding. Its largest reduction was Pulmonx, cutting an estimated $31.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • ABG-WTT Global Life Science Capital Partners's biggest Q2 2021 reduction was Pulmonx, cutting an estimated $31.4M.
  • ABG-WTT Global Life Science Capital Partners's ten largest holdings make up 100% of its $51.7M portfolio in Q2 2021.
  • ABG-WTT Global Life Science Capital Partners opened 0 new positions and closed 0 in Q2 2021.
  • ABG-WTT Global Life Science Capital Partners's portfolio value fell 44% quarter-over-quarter to $51.7M.

Based on ABG-WTT Global Life Science Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.